Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Q2 FY24 Post results Earnings Call details01-11-2023
01-11-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
Update on acquisition31-10-2023
Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under Reg 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201531-10-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus acquires UK based LiqMeds Group.31-10-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Acquisition
Acquisition31-10-2023
Zydus Lifesciences Ltd - 532321 - Board Meeting Intimation for Notice For The Meeting Of Board Of Directors
Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2023 ,inter alia, to consider and approve the unaudited financial results for the quarter / half year ended on September 30, 2023.30-10-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus and Sun Pharma sign licensing agreement for co-marketing of Desidustate, a critical treatment for Chronic Kidney Disease patients in India.30-10-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
The Newspaper Publication of Notice of loss of share certificate of the Company, published in the Financial Express English and Gujarati Editions, both on October 28, 2023.28-10-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Lifesciences initiates Phase II clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS).25-10-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives USFDA approval for ZITUVIO to treat adult patients with type 2 diabetes mellitus.20-10-2023